AR101 Oral Immunotherapy for Peanut Allergy

Area of Science:

• Immunology
• Allergy and Immunology
• Clinical Trials

Background:

• Peanut allergy affects individuals with unpredictable, potentially life-threatening reactions.
• Currently, no approved treatment options exist for peanut allergy.
• Investigational biologic oral immunotherapy aims to improve tolerance in peanut-allergic patients.

Purpose of the Study:

• To evaluate the efficacy and safety of AR101 (peanut oral immunotherapy) in children and adolescents with peanut allergy.
• To determine if AR101 can increase the threshold for eliciting allergic reactions to peanut protein.
• To compare AR101 treatment against a placebo in a double-blind, food challenge setting.

Main Methods:

• A phase 3, double-blind, placebo-controlled trial involving participants aged 4-55 with peanut allergy.
• Participants with allergic reactions to low-dose peanut protein were randomized to AR101 or placebo.
• An escalating-dose regimen was followed by a maintenance phase, culminating in an exit food challenge.

Main Results:

• 67.2% of participants (4-17 years) on AR101 tolerated 600mg peanut protein vs. 4.0% on placebo (P<0.001).
• AR101 treatment led to significantly lower symptom severity during the exit food challenge compared to placebo.
• Adverse events were common, but severe events were infrequent in both active and placebo groups.

Conclusions:

• AR101 oral immunotherapy demonstrated efficacy in increasing peanut protein tolerance in children and adolescents.
• The treatment resulted in reduced symptom severity upon peanut exposure.
• Efficacy was not observed in adult participants (18+ years).